Pharmaceutical manufacturers are upgrading production infrastructure from traditional batch processing to continuous bioprocessing systems. The operational overhaul aims to accelerate turnaround times for complex monoclonal antibodies and recombinant proteins.
Quality Control via Real-Time Analytics
Integrated Process Analytical Technology (PAT) allows continuous monitoring of critical quality attributes during synthesis. This real-time oversight significantly lowers batch rejection rates and minimizes operational down-time.